Hyperbaric oxygen therapy for acute coronary syndrome - PubMed (original) (raw)

Review

Hyperbaric oxygen therapy for acute coronary syndrome

Michael H Bennett et al. Cochrane Database Syst Rev. 2015.

Abstract

Background: Acute coronary syndrome (ACS), includes acute myocardial infarction and unstable angina, is common and may prove fatal. Hyperbaric oxygen therapy (HBOT) will improve oxygen supply to the threatened heart and may reduce the volume of heart muscle that perishes. The addition of HBOT to standard treatment may reduce death rate and other major adverse outcomes.This an update of a review previously published in May 2004 and June 2010.

Objectives: The aim of this review was to assess the evidence for the effects of adjunctive HBOT in the treatment of ACS. We compared treatment regimens including adjunctive HBOT against similar regimens excluding HBOT. Where regimens differed significantly between studies this is clearly stated and the implications discussed. All comparisons were made using an intention to treat analysis where this was possible. Efficacy was estimated from randomised trial comparisons but no attempt was made to evaluate the likely effectiveness that might be achieved in routine clinical practice. Specifically, we addressed:Does the adjunctive administration of HBOT to people with acute coronary syndrome (unstable angina or infarction) result in a reduction in the risk of death?Does the adjunctive administration of HBOT to people with acute coronary syndrome result in a reduction in the risk of major adverse cardiac events (MACE), that is: cardiac death, myocardial infarction, and target vessel revascularization by operative or percutaneous intervention?Is the administration of HBOT safe in both the short and long term?

Search methods: We updated the search of the following sources in September 2014, but found no additional relevant citations since the previous search in June 2010 (CENTRAL), MEDLINE, EMBASE, CINAHL and DORCTHIM. Relevant journals were handsearched and researchers in the field contacted. We applied no language restrictions.

Selection criteria: Randomised studies comparing the effect on ACS of regimens that include HBOT with those that exclude HBOT.

Data collection and analysis: Three authors independently evaluated the quality of trials using the guidelines of the Cochrane Handbook and extracted data from included trials. Binary outcomes were analysed using risk ratios (RR) and continuous outcomes using the mean difference (MD) and both are presented with 95% confidence intervals. We assessed the quality of the evidence using the GRADE approach.

Main results: No new trials were located in our most recent search in September 2014. Six trials with 665 participants contributed to this review. These trials were small and subject to potential bias. Only two reported randomisation procedures in detail and in only one trial was allocation concealed. While only modest numbers of participants were lost to follow-up, in general there is little information on the longer-term outcome for participants. Patients with acute coronary syndrome allocated to HBOT were associated with a reduction in the risk of death by around 42% (RR: 0.58, (95% CI 0.36 to 0.92), 5 trials, 614 participants; low quality evidence).In general, HBOT was well-tolerated. No patients were reported as suffering neurological oxygen toxicity and only a single patient was reported to have significant barotrauma to the tympanic membrane. One trial suggested a significant incidence of claustrophobia in single occupancy chambers of 15% (RR of claustrophobia with HBOT 31.6, 95% CI 1.92 to 521).

Authors' conclusions: For people with ACS, there is some evidence from small trials to suggest that HBOT is associated with a reduction in the risk of death, the volume of damaged muscle, the risk of MACE and time to relief from ischaemic pain. In view of the modest number of patients, methodological shortcomings and poor reporting, this result should be interpreted cautiously, and an appropriately powered trial of high methodological rigour is justified to define those patients (if any) who can be expected to derive most benefit from HBOT. The routine application of HBOT to these patients cannot be justified from this review.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1

1

Study flow diagram

2

2

Forest plot of comparison: 1 Death, outcome: 1.1 Death at any time.

1.1

1.1. Analysis

Comparison 1: Death, Outcome 1: Death at any time

1.2

1.2. Analysis

Comparison 1: Death, Outcome 2: Death ‐ best case scenario

1.3

1.3. Analysis

Comparison 1: Death, Outcome 3: Death ‐ worst case scenario

2.1

2.1. Analysis

Comparison 2: Major Adverse Cardiac Events, Outcome 1: Major Adverse Cardiac Events

2.2

2.2. Analysis

Comparison 2: Major Adverse Cardiac Events, Outcome 2: MACE ‐ Best case scenario

2.3

2.3. Analysis

Comparison 2: Major Adverse Cardiac Events, Outcome 3: MACE ‐ worst case scenario

2.4

2.4. Analysis

Comparison 2: Major Adverse Cardiac Events, Outcome 4: Recurrent acute myocardial infarction (AMI)

2.5

2.5. Analysis

Comparison 2: Major Adverse Cardiac Events, Outcome 5: Recurrent AMI ‐ best case scenario

2.6

2.6. Analysis

Comparison 2: Major Adverse Cardiac Events, Outcome 6: Recurrent AMI ‐ Worst case scenario

3.1

3.1. Analysis

Comparison 3: Significant dysrhythmias (complete heart block, ventricular fibrillation, asystole), Outcome 1: Overall (CHB, VF and asystole combined)

3.2

3.2. Analysis

Comparison 3: Significant dysrhythmias (complete heart block, ventricular fibrillation, asystole), Outcome 2: Significant dysrrythmias (complete heart block, ventricular fibrillation or asystole)

3.3

3.3. Analysis

Comparison 3: Significant dysrhythmias (complete heart block, ventricular fibrillation, asystole), Outcome 3: Overall best case

3.4

3.4. Analysis

Comparison 3: Significant dysrhythmias (complete heart block, ventricular fibrillation, asystole), Outcome 4: Overall worst case

4.1

4.1. Analysis

Comparison 4: Time to pain relief, Outcome 1: Time to relief of pain

5.1

5.1. Analysis

Comparison 5: Magnitude of cardiac enzyme changes, Outcome 1: 12 hour Plasma Creatine Phosphokinase

5.2

5.2. Analysis

Comparison 5: Magnitude of cardiac enzyme changes, Outcome 2: 24 hour Plasma Creatine Phosphate

5.3

5.3. Analysis

Comparison 5: Magnitude of cardiac enzyme changes, Outcome 3: Maximum Plasma Creatine Phosphate

6.1

6.1. Analysis

Comparison 6: Improvement in left ventricular function, Outcome 1: Improved contraction in at least one segment (post‐HBOT echo)

6.2

6.2. Analysis

Comparison 6: Improvement in left ventricular function, Outcome 2: Left Ventricular Ejection Fraction‐ % (final estimate)

7.1

7.1. Analysis

Comparison 7: Length of Stay, Outcome 1: Overall length of stay (days)

8.1

8.1. Analysis

Comparison 8: Adverse events of therapy, Outcome 1: Total adverse events

Update of

Similar articles

Cited by

References

References to studies included in this review

Dekleva 2004 {published data only}
    1. Dekleva M, Neskovic A, Vlahovic A, Putnikovic B, Beleslin B, Ostojic M. Adjunctive effect of hyperbaric oxygen treatment after thrombolysis on left ventricular function in patients with acute myocardial infarction. American Heart Journal 2004;148:e14. - PubMed
    1. Vlahovic A, Neskovic AN, Dekleva M, Putnikovic B, Popovic ZB, Otasevic P, et al. Hyperbaric oxygen treatment does not affect left ventricular chamber stiffness after myocardial infarction treated with thrombolysis. American Heart Journal 2004;148:e1. - PubMed
Dotsenko 2007 {published data only}
    1. Aliprandi-Costa B, Ranasinghe I, Chow V, Kapila S, Juergens C, Devlin G, et la. Management and outcomes of patients with acute coronary syndromes in Australia and New Zealand, 2000–2007. MJA 2011;195(3):116-21. - PubMed
    1. Dotsenko EA, Salivonchik OP, Kozyro VI. Long term results of the use of hyperbaric oxygenation in patients with acute myocardial infarction. Kardiologiia 2007;12:53-6. - PubMed
    1. Dotsenko EA, Salivonchik OP, Nikulina N, Welcome MO. The influence of hyperbaric oxygenation therapy on recurrent myocardial infarction and two-year survival rate in acute myocardial infarction patients. Port Harcourt Medical Journal 2009;3(3):256-63.
Hot MI 1998 {published data only}
    1. Dekleva MN, Ostojic M, Vujnovic D. Hyperbaric oxygen and thrombolysis in acute myocardial infarction: a preliminary report. In: Sitinen SA, Leinio M, editors(s). Proceedings of the Twenty-first Annual Meeting of the European Underwater and Baromedical Society (EUBS). Helsinki: EUBS, 1995:9-13.
    1. Shandling AH, Ellestad MH, Hart GB, Crump R, Marlow D, Van Natta B, et al. Hyperbaric oxygen and thrombolysis in myocardial infarction: The "HOT MI" pilot study. American Heart Journal 1997;134:544-50. - PubMed
    1. Stavitsky Y, Shandling AH, Ellestad MH, Hart GB, Van Natta B, Messenger JC, et al. Hyperbaric oxygen and thrombolysis in myocardial infarction: the 'HOT MI' randomised multicenter study. Cardiology 1998;90:131-6. - PubMed
Sharifi 2004 {published data only}
    1. Sharifi M, Fares W, Abdel-Karim I, Koch JM, Sopko J, Adler D. Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris. American Journal of Cardiology 2004;93(June 15):1533-5. - PubMed
    1. Sharifi M, Fares W, Abdel-Karim I, Petrea D, Koch JM, Adler D, et al. Inhibition of restenosis by hyperbaric oxygen: a novel indication for an old modality. Cardiovascular Radiation Medicine 2002;3:124-6. - PubMed
Swift 1992 {published data only}
    1. Swift PC, Turner JH, Oxer HF, O'Sea JP, Lane GK, Woollard KV. Myocardial hibernation identified by hyperbaric oxygen treatment and echocardiography in postinfarction patients: comparison with exercise thallium scintigraphy. American Heart Journal 1992;124:1151-8. - PubMed
Thurston 1973 {published data only}
    1. Thurston GJ, Greenwood TW, Bending MR, Connor H, Curwen MP. A controlled investigation into the effects of hyperbaric oxygen on mortality following acute myocardial infarction. Quarterly Journal of Medicine 1973;XLII:751-70. - PubMed

References to studies excluded from this review

Cameron 1965 {published data only}
    1. Cameron AJ, Gibb BH, Ledingham I. A controlled clinical trial of hyperbaric oxygen in the treatment of acute myocardial infarction. In: Ledingham I , editors(s). Hyperbaric Oxygenation: Proceedings of the Second International Congress. London: ES Livingstone, 1965:277.
Ciocatto 1965 {published data only}
    1. Ciocatto E, Moricca G, Querci M, Cabrai M. Experimental studies on hyperbaric oxygenation. Panminerva Medica 1965;7(11):419-24. - PubMed
Dai 1995 {published data only}
    1. Dai R, Wu JT, Liu LP, Wang YQ. Hyperbaric oxygen for coronary heart disease. Chinese Journal of Physical Therapy 1995;18:236-7.
Markarian 1991 {published data only}
    1. Markarian SS, Shirinskaia GI, Starostin SG, Zagvozkin VN. Comparative study of the effect of drug therapy and its combination with hyperbaric oxygenation and hemosorption on stable angina pectoris [Sravnitel'noe izuchenie vliiania medikamentoznoi terapii i ee sochetanii s giperbaricheskoi oksigenatsiei i gemocorbtsiei na stabil'nuiu stenokardiiu]. Kardiologiia 1991;31(9):40-2. - PubMed
Thomas 1990 {published data only}
    1. Thomas MP, Brown LA, Sponseller DR, Williamson SE, Diaz JA, Guyton DP. Myocardial infarct size reduction by the synergistic effect of hyperbaric oxygen and recombinant tissue plasminogen activator. American Heart Journal 1990;120(4):791-800. - PubMed

Additional references

Ashfield 1969
    1. Ashfield R, Drew CE, Gavey CJ. Severe acute myocardial infarction treated with hyperbaric oxygen. Postgraduate Medical Journal 1969;45:648-53. - PMC - PubMed
Bennett 2002
    1. Bennett. The database of randomised controlled trials in hyperbaric medicine. www.hboevidence.com (accessed on 21 February 2005).
BHF 2012
    1. British Heart Foundation. https://www.bhf.org.uk/publications/statistics/coronary-heart-disease-st.... London: British Heart Foundation, 3/12/2012.
Boerema 1960
    1. Boerema I, Meyne NG, Brummelkamp WK, Bouma S, Mensch MH, Kamermans F, et al. Life without blood: a study of the influence of high atmospheric pressure and hypothermia on dilution of blood. Journal of Cardiovascular Surgery 1960;1(1):133-46.
Butler 2008
    1. Butler FK, Hagan C. Ocular complications in hyperbaric oxygen therapy. In: Neuman T, Thom S, editors(s). Physiology and Medicine of Hyperbaric Oxygen Therapy. 1st edition. Philadelphia: Saunders Elsevier, 2008:265-72.
Clark 2008
    1. Clarke JM. Oxygen toxicity. In: Neuman T, Thom S, editors(s). Physiology and Medicine of Hyperbaric Oxygen Therapy. 1st edition. Philadelphia: Saunders Elsevier, 2008:527-564.
Ellestad 2009
    1. Ellestad MH. Hyperbaric oxygen: its application in cardiology: a historical perspective and personal journey. Cardiology Review 2009;17(6):280-2. - PubMed
Hammarlund 1999
    1. Hammarlund C. The physiologic effects of hyperbaric oxygenation. In: Kindwall EP, Whelan HT, editors(s). Hyperbaric Medicine Practice. 2nd edition. Flagstaff Az: Best Publishing Company, 1999:37-68.
Harabin 1990
    1. Harabin AL, Braisted JC, Flynn ET. Response of antioxidant enzymes to intermittent and continuous hyperbaric oxygen. Journal of Applied Physiology 1990;69(1):328-35. - PubMed
Heistad 2003
    1. Heistad D. Unstable coronary-artery plaques. New England Journal of Medicine 2003;349(24):2285-7. - PubMed
Heyboer 2014
    1. Heyboer M, Milovanova TN, Wojcik S, Grant W, Chin M, Hardy KR, et al. CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen - changes withb oxygen dosing. Stem Cell Research 2014;12(3):638-45. - PMC - PubMed
Higgins 2008
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Book Series. Chichester: Wiley-Blackwell, 2008.
Jain 2009
    1. Jain KK. Textbook of Hyperbaric Medicine. 5th edition. Seattle: Hogrefe and Huber, 2009.
Jones 2010
    1. Jones SR, Carpin KM, Woodward SM, Khiabani KT, Stephenson LL, Wang WZ, et al. Hyperbaric oxygen Inhibits ischemia-reperfusion–induced neutrophil CD18Polarization by a nitric oxide mechanism. Plastic and Reconstructive Surgery 2010;126(2):403-11. - PMC - PubMed
Kalla 2006
    1. Kalla K, Christ G, Karnik R, Malzer R, Norman G, Prachar H, et al. Implementation of guidelines improves the standard of care the Viennese Registry on Reperfusion Strategies in ST-Elevation Myocardial Infarction (Vienna STEMI Registry). Circulation 2006;113:2398-405. - PubMed
Khan 2003
    1. Khan B, Evans AW, Easterbrook M. Refractive changes in patients undergoing hyperbaric oxygen therapy: a prospective study. Undersea and Hyperbaric Medicine 2003;24:9.
Kindwall 2008
    1. Kindwall EP, Whelan HT. Hyperbaric Medicine Practice. 3rd edition. Flagstaff: Best Publishing Company, 2008.
Kline 1970
    1. Kline HJ, Marano AJ, Johnson CD, Goodman P, Jacobson JH, Kuhn LA. Hemodynamic and metabolic effects of hyperbaric oxygenation in myocardial infarction. Journal of Applied Pathology 1970;28:256-63. - PubMed
Leach 1998
    1. Leach RM, Rees PJ, Wilmshurst P. ABC of oxygen. Hyperbaric oxygen therapy. BMJ 1998;317:1140-3. - PMC - PubMed
Mathieu 2006
    1. Mathieu D. Handbook on Hyperbaric Medicine. 2nd edition. Milan: Springer, 2006.
Moon 1964
    1. Moon AJ, Williams KG, Hopkinson WI. A patient with coronary thrombosis treated with hyperbaric oxygen. Lancet 1964;1:18-20. - PubMed
Naghavi 2003
    1. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003;108(14):1664-72. - PubMed
Nichols 2012
    1. Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Grey A, Scarborough P, Rayner M. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis. Brussels: European Society of Cardiology, Sophia Antipolis, 2012.
Sheffield 1988
    1. Sheffield P. Tissue oxygen measurements. In: Problem Wounds. The Role of Oxygen. 1st edition. New York: Elsevier Science Publishing, 1988:17-51.
Shupak 2008
    1. Shupak A, Gilbey P. Effects of pressure. In: Neuman T, Thom S, editors(s). Physiology and Medicine of Hyperbaric Oxygen Therapy. 1st edition. Philadelphia: Saunders Elsevier, 2008:513-26.
Smith 1958
    1. Smith G, Lawson DA. Experimental coronary arterial occlusion: effects of the administration of oxygen under pressure. Scottish Medical Journal 1958;3:346-50. - PubMed
Speit 2000
    1. Speit G, Dennog C, Eichorn U, Rothfuss A, Kaina B. Induction of heme oxygenase-1 and adaptive protection against the induction of DNA damage after hyperbaric oxygen treatment. Cardiogenesis 2000;21(10):1795-9. - PubMed
Thom 1991
    1. Thom SR, Elbuken M. Oxygen-dependent antagonism of lipid peroxidation in the rat. Free Radical Biology and Medicine 1991;10(6):413-26. - PubMed
Thom 2009
    1. Thom S. Oxidative stress is fundamental to hyperbaric oxygen therapy. Journal of Applied Physiology 2009;106:988-95. - PMC - PubMed
Tjarnstrom 1999
    1. Tjarnstrom J, Wikstrom T, Bagge U. Effects of hyperbaric oxygen treatment on neutrophil activation and pulmonary sequestration in intestinal ischemia-reperfusion in rats. European Surgical Research 1999;31(2):147-54. - PubMed
Wells 1977
    1. Wells CH, Goodpasture JE, Horrigan DJ. Tissue gas measurements during hyperbaric oxygen exposure. In: Smith G , editors(s). Proceedings of the Sixth International Congress on Hyperbaric Medicine. Aberdeen: Aberdeen University Press, 1977:118-24.
WHO 2013
    1. World Health Organisation. Cardiovascular diseases (CVDs). Fact sheet N°317 Updated March 2013. http://www.who.int/mediacentre/factsheets/fs317/en/ (accessed on 19 December 2014).

Publication types

MeSH terms

LinkOut - more resources